The post is about a user starting a hair loss treatment using finasteride, micro needling, and nizoral. The conversation includes supportive replies from other users.
The conclusion of this conversation is that the user "DuckSeasonCamelSeasn" found that consuming grapefruit juice prior to taking finasteride or dutasteride helped them become a responder to the medications and regain hair growth. However, there are warnings about potential risks and interactions with other medications, so caution should be exercised.
A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.
The conversation discusses hair loss treatments including finasteride, minoxidil, derma rolling, and tretinoin, with the user showing progress after five months. Tretinoin is mentioned to enhance the effectiveness of minoxidil.
The user is experimenting with a mix of topical treatments, including finasteride and minoxidil, to improve hair growth, particularly at the temples and core. They are also trying various oils, despite skepticism about their effectiveness, to see if they can enhance results without causing harm.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
A user is seeking recommendations for doctors who perform Dutasteride mesotherapy in NJ or PA, as they are having trouble finding one through Google. The conversation focuses on finding a suitable provider for this specific hair loss treatment.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.
The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.
The conversation discusses using a combination of DHT gel, dutasteride, pyrilutamide, and minoxidil to promote beard growth while minimizing hair loss. Users suggest consulting a doctor and considering genetic factors before proceeding.
Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.
The conversation is about whether the Ordinary's Multi-Peptide Serum for hair density can be mixed with finasteride. A video was mentioned that shows the serum being mixed with Stemoxydine.
The conversation discusses creating a personalized topical treatment for hair loss, with ingredients like finasteride, minoxidil, tretinoin, melatonin, caffeine, and others. Users share their ideal formulations, including combinations of minoxidil, finasteride, tretinoin, adenosine, and other compounds, while also discussing the importance of managing inflammation.
Petal Fresh Hair ResQ shampoo is discussed for hair loss, with skepticism about its effectiveness. Minoxidil is mentioned as part of a treatment plan, and other recommended ingredients include Piroctone Olamine, Ketoconazole, and Saw Palmetto.
The conversation discusses using pumpkin seed oil and rosemary oil for hair thinning, with skepticism about their effectiveness compared to pharmaceutical options like finasteride and minoxidil. Some users suggest trying natural treatments, while others emphasize the proven success of pharmaceuticals.
Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.
The conversation discusses hair loss treatment progress over three months using Minoxidil, Finasteride, weekly derma rolling, a bamboo brush, and vitamins Biotin, D, and Saw Palmetto. The user reports noticing hair regrowth at the temples.
Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.
A user shared a discount code for RU58841 from Anagen Inc, which some users find effective for hair loss without side effects. Another user expressed skepticism about the safety of RU58841 due to limited research.